Spain has presented the Profarma programme, which evaluates and supports pharmaceutical companies operating in the country. The programme considers industrial capacity, research and innovation, quality employment, exports, public-private cooperation and sustainability. Fifty-four companies participated in the 2025 edition, and 43 were selected as beneficiaries. Spain’s pharmaceutical industry generates value added equivalent to around 2% of national GDP.
Spain has presented the Profarma programme as a key instrument for strengthening the competitiveness of its pharmaceutical industry.
Profarma evaluates pharmaceutical companies operating in Spain and provides incentives to businesses that demonstrate strong industrial, research and employment performance.
The programme is jointly managed by the ministries responsible for industry and tourism, health, and science, innovation and universities.
Its assessment is not limited to medicine sales. It covers manufacturing capacity, research, development and innovation, quality employment, exports, public-private collaboration and environmental sustainability.
Spain’s pharmaceutical industry generates value added equivalent to approximately 2% of the country’s gross domestic product, or GDP.
The sector connects manufacturing plants, laboratories, clinical development, supply chains, exports and highly qualified employment. National production capacity is important not only for economic growth but also for the reliable supply of medicines.
Profarma has operated for more than three decades. The government describes it as a programme that has encouraged industrial investment, pharmaceutical research, qualified employment and export capacity.
Companies receive ratings based on their performance. Qualifying companies may receive reductions in certain contributions made to Spain’s National Health System.
Fifty-four pharmaceutical companies participated in the 2025 edition, and 43 were selected as beneficiaries.
The programme is also linked to European efforts to improve strategic autonomy in medicines and health technology.
Strategic autonomy refers to the ability to secure essential medicines, manufacturing capacity, active ingredients and critical technology without excessive dependence on external suppliers.
The programme addresses innovative medicines, strategic medicines, advanced therapies, biomedical innovation, digital transformation, sustainability and supply-chain resilience.
Advanced therapies include areas such as gene therapy, cell therapy and tissue engineering. These fields require substantial research investment and specialist expertise but may provide new options for rare and difficult-to-treat diseases.
Spain also aims to expand cooperation among pharmaceutical companies, hospitals, universities, research centres, public authorities and biotechnology startups.
Medicine development involves a long process covering basic research, clinical trials, authorisation, manufacturing and delivery to patients. Cooperation among institutions is required throughout these stages.
Profarma may help Spain attract new manufacturing plants, research activity and investment while strengthening its position as a European pharmaceutical centre.
The expansion of the sector can also increase demand for specialists in chemistry, life sciences, medicine, data analysis, quality management and regulatory affairs.
Industrial support must nevertheless be assessed alongside medicine affordability, patient access and the financial sustainability of the public health system.
The next issues to monitor will be whether beneficiary companies expand investment, research, production and employment in Spain and whether the programme improves medicine supply and access to innovative treatment.